Articles

Making sense of pharma’s financial relationships with physicians

25th November 2014

Making sense of pharma’s financial relationships with physiciansAshish Kalgaonkar

Details of payments made to doctors and hospitals in the US are now available to view online, as necessitated by the 'Sunshine Act' health care reforms. So what does this... Read more

Access strategy for success in emerging markets

24th November 2014

Access strategy for success in emerging marketsWilliam Kammerer and Anastasia Thatcher

Over the past two decades nations of lower-middle income and upper-middle-class consumers have developed. This 'Emerging Middle Class', with an average per capita income of between $1,000 and $12,000, now... Read more

The ills inflicted by poor strategy

21st November 2014

The ills inflicted by poor strategy Candice O’Sullivan

If brand managers adopt a policy of 'doing no harm', as doctors do, then strategies will be taken seriously and the outcomes will be the best possible, for the brand... Read more

Facebook and pharma in 2014

20th November 2014

Facebook and pharma in 2014Stefan Marcus

Ten years on, Facebook remains an important channel through which pharma can engage with patients. What has been learned in that time and how have communication strategies evolved within the... Read more

News

BioMarin offers $840m for muscular dystrophy firm Prosensa

25th November 2014

BioMarin offers $840m for muscular dystrophy firm ProsensaStaff reporter

Rare disease specialist BioMarin has agreed to acquire Prosensa and its Duchenne muscular dystrophy (DMD) candidate drisapersen in a deal valued at up to around $840 million. The US company... Read more

IMS Health partners with pharmaphorum on cancer educational programme

25th November 2014

IMS Health partners with pharmaphorum on cancer educational programmeLinda Banks

With the approach of the General Election, healthcare strategies, budgets, the NHS and the future of the Cancer Drugs Fund are all in the headlines and pharmaphorum has its finger... Read more

AstraZeneca COPD drug combination approved in EU

24th November 2014

AstraZeneca COPD drug combination approved in EULinda Banks

AstraZeneca's (AZ) Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation (MA) by the European Commission (EC) for use as a maintenance bronchodilator treatment to relieve symptoms... Read more

AbbVie's oral hepatitis C regimen backed for EU approval

24th November 2014

AbbVie's oral hepatitis C regimen backed for EU approvalStaff reporter

AbbVie has closed in on the first approval of its four-drug hepatitis C virus regimen, after the EU's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion... Read more

Audio & Video

Dec 8th: Live webinar - The Price is Rig…

Slide-300x200b

 

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the... View more

Now on demand - real world insight into …

The Diabetes Debate

 

Now available on demand (free to access) - originally broadcast on October 29th 2014.


Non-adherence to self-management regimens in diabetes is globally... View more

On-demand webinar: Is pharma brand marke…

Kantar Health webinar


While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to... View more

View the conversation - Tweetchat: Manag…

Atlantis Healthcare diabetes Tweetchat


Working in partnership, Atlantis Healthcare and pharmaphorum conducted a Tweetchat focussed on the real world challenges patients face in managing... View more

White Papers

"The future ain’t what it used to b…

"The future ain’t what it used to be"Paul Stuart-Kregor

Preparation is key to creating and maintaining a strong drugs pipeline. However, the statistics demonstrate that successful product commercialisation strategies are not always implemented. Products are developed for which there... View info

Healthcare Innovation: the big ideas sha…

Healthcare Innovation: the big ideas shaping the future of pharmaDavid Rowley

The transformation taking place in healthcare is challenging for everyone and adaptability is key for the pharma industry's continued success.

Long production cycles, concentration on specialist drugs with high... View info

Giving a voice to those with heart valve…

Giving a voice to those with heart valve disease

Although over a million people in the UK today have heart valve disease, it remains an overlooked condition. Despite the priority being given to cardiovascular disease in the UK, it... View info

Pricing & Market Access Outlook 2014

Pricing & Market Access Outlook 2014

Pricing and market access are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need,... View info

Further News & Articles

RB spin-out Indivior says addiction pipeline will deliver

Earlier this week, Reckitt Benckiser (RB) made good on its promise to spin-out its pharmaceutical business in... Read more

News

Novartis novel psoriasis treatment gains positive opinion in Europe

Novartis' Cosentyx (secukinumab) is the first IL-17A inhibitor to receive a positive opinion from the Europea... Read more

News

UK aims to shave years off drug development

The UK government has announced an 'end to end' review of how drugs are developed, approved and accessed by pati... Read more

News

Stratified medicine shows promise for NHS

New research from the Association of the British Pharmaceutical Industry (ABPI) shows that 90 per cent of clinic... Read more

News

Shire moves 500 jobs to Massachusetts

An efficiency programme begun at Shire before the AbbVie takeover bid has now resumed, with 500 jobs being re... Read more

News

'Efficiency-driven' M&A is here to stay, says Shire chief

Andrew McConaghie reports on contrasting views on 2014's merger and acquisition rollercoaster ride, and the ... Read more

Articles